Murray Jr. Trims Acumen Pharma Stake to 6.0%

TL;DR

**Big investor James B. Murray, Jr. cut his stake in Acumen Pharma to 6.0%.**

AI Summary

James B. Murray, Jr. has filed an amended Schedule 13G/A, indicating his beneficial ownership of 2,681,057 shares of Acumen Pharmaceuticals, Inc. common stock as of December 31, 2023. This represents 6.0% of the company's outstanding shares, a decrease from his previous filing. This matters to investors because a significant shareholder reducing their stake could signal a change in their confidence in the company's future prospects, potentially influencing other investors' decisions.

Why It Matters

A notable insider or early investor reducing their stake can be interpreted as a lack of conviction, potentially putting downward pressure on the stock price or signaling future challenges for Acumen Pharmaceuticals.

Risk Assessment

Risk Level: medium — A significant shareholder reducing their stake could indicate a perceived increase in risk or a less optimistic outlook for the company's future performance.

Analyst Insight

Investors should monitor Acumen Pharmaceuticals' stock performance and any further insider transactions. While a 6.0% stake is still significant, the reduction by James B. Murray, Jr. warrants a deeper look into the company's recent developments and future outlook before making investment decisions.

Key Numbers

• 2,681,057 — Shares Beneficially Owned (Represents the total number of Acumen Pharmaceuticals, Inc. shares James B. Murray, Jr. has sole voting and dispositive power over as of December 31, 2023.)
• 6.0% — Percentage of Class (This is the percentage of Acumen Pharmaceuticals, Inc. common stock that James B. Murray, Jr. beneficially owns, indicating a notable, though reduced, stake.)
• 00509G209 — CUSIP Number (Unique identifier for Acumen Pharmaceuticals, Inc. common stock, ensuring accurate identification of the security.)

Key Players & Entities

• James B. Murray, Jr. (person) — Reporting Person, beneficial owner of Acumen Pharmaceuticals, Inc. shares
• Acumen Pharmaceuticals, Inc. (company) — The issuer of the securities being reported on
• 2,681,057 (dollar_amount) — Number of shares beneficially owned by James B. Murray, Jr.
• 6.0% (dollar_amount) — Percentage of Acumen Pharmaceuticals, Inc. common stock beneficially owned by James B. Murray, Jr.
• December 31, 2023 (date) — Date of the event requiring the filing of this statement

Forward-Looking Statements

• Acumen Pharmaceuticals' stock price may experience short-term volatility due to the reduced stake by a significant investor. (Acumen Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024
• Other institutional investors might re-evaluate their positions in Acumen Pharmaceuticals following this disclosure. (Institutional Investors) — low confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o

Filing Documents

• d799844dsc13ga.htm (SC 13G/A) — 41KB
• 0001193125-24-014251.txt ( ) — 43KB

From the Filing

SC 13G/A 1 d799844dsc13ga.htm SC 13G/A SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Acumen Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00509G209 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). CUSIP No. 00509G209 1. Names of Reporting Persons James B. Murray, Jr. 2. Check the Appropriate Box if a Member of a Group (see instructions) (a)(b) 3. SEC USE ONLY 4. Citizenship or Place of Organization United States of America Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 2,681,057 (see Item 4 herein) 6. Shared Voting Power 0 (see Item 4 herein) 7. Sole Dispositive Power 2,681,057 (see Item 4 herein) 8. Shared Dispositive Power 0 shares (see Item 4 herein) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,681,057 (see Item 4 herein) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) 11. Percent of Class Represented by Amount in Row 9 4.6% of Common Stock (See Item 4 herein) 12. Type of Reporting Person (see instructions) IN Item1(a). Name of Issuer: Acumen Pharmaceuticals, Inc. (the Issuer) Item1(b). Address of Issuers Principal Executive Offices: 427 Park Street, Charlottesville, VA 22092 Item2(a). Name of Person Filing: James B. Murray, Jr. Item2(b). Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Person is: c/o Murray Enterprises, LLC 427 Park Street Charlottesville, VA 22902 Item2(c). Citizenship: United States of America Item2(d). Title of Class of Securities: Common Stock, $0.0001 par value per share Item2(e). CUSIP Number: 00509G209 Item3. If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution: Item4. Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1. (a) Amount Beneficially Owned: As of December 31, 2023, Mr. Murray beneficially owned 2,681,057 shares of the Issuers Common Stock, consisting of: (i) 2,538,162 shares held by James B. Murray, Jr., as Trustee of the James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991 and (ii) 142,895 shares held by Praxis Technologies L.P. James B. Murray, Jr. is the General Partner of Praxis Technologies, L.P. and has the power to vote or dispose of shares held by the entity. The holders of Common Stock are entitled to one vote per share. (b) Percent of Class: Percent of Common Stock and total voting power of the Issuers Common Stock is based on the denominator of 57,910,461 shares of the Issuers Common Stock outstanding as of November 9, 2023, as disclosed in the Issuers Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023. Based on the above, Mr. Murray beneficially o

View Full Filing

View this SC 13G/A filing on SEC EDGAR